Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 1/20 | 0.41 |
| ▸ | LIG1 | P18858 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8268878 | 1.00 | PCNA (0.41) | PCNALIG1IDO1DPP4TRPA1 | |
| Trifluoroacetic Acid SCHEMBL4358439 | 0.88 | GRB2 (0.40) | PCNALIG1DPP4EPHX1SLC1A1 | |
| Trifluoroacetic Acid SCHEMBL4358433 | 0.88 | GRB2 (0.40) | PCNALIG1DPP4EPHX1SLC1A1 | |
| SCHEMBL4823652 | 0.82 | IDO1 (0.36) | IDO1DPP4TRPA1EPHX1SLC1A1 | |
| SCHEMBL8271157 | 0.81 | EPHX1 (0.48) | TRPA1EPHX1SLC6A4SLC1A1ANPEP | |
| SCHEMBL7967754 | 0.80 | SLC1A1 (0.55) | IDO1DPP4EPHX1SLC1A1ANPEP | |
| SCHEMBL5230103 | 0.80 | SLC1A1 (0.55) | IDO1DPP4EPHX1SLC1A1ANPEP | |
| SCHEMBL5230112 | 0.80 | SLC1A1 (0.55) | IDO1DPP4EPHX1SLC1A1ANPEP | |
| SCHEMBL1568278 | 0.80 | IDO1 (0.41) | IDO1DPP4EPHX1SLC6A4SLC1A1 | |
| SCHEMBL4874729 | 0.80 | TRPA1 (0.59) | IDO1DPP4TRPA1EPHX1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | ELAN PHARMACEUTICALS, INC. (US) | 2008-07-10 | — | — | US | disclosed |
| EP-1802574-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ETHANOL CYCLICAMINE DERIVATIVES ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| EP-1789388-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS | Elan Pharmaceuticals, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060074098-A1 | Methods of treatment of amyloidosis using ethanolcyclicamine aspartyl protease inhibitors | ELAN PHARMACEUTICALS, INC. | 2006-04-06 | — | — | US | disclosed |
| WO-2006026532-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| WO-2006026533-A2 | METHODS OF TREATMENT OF AMYLOIDOSIS USING ETHANOL CYCLICAMINE DERIVATIVES ASPARTYL PROTEASE INHIBITORS | ELAN PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166332-A1 | Methods of Treatment of Amyloidosis Using Subsituted Ethanolcyclicamine Aspartyl Protease Inhibitors | AMY1A, AMY2A, DNPEP | PCNA 2516/4885LIG1 2818/4885IDO1 3635/4885 |
| US-20060074098-A1 | Methods of treatment of amyloidosis using ethanolcyclicamine aspartyl protease inhibitors | DNPEP, AMY1A, AMY2A | PCNA 1754/4885LIG1 2284/4885IDO1 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.